Advacan 0.25mg Tablet

Advacan 0.25mg tablet is an antineoplastic drug belonging to the class of mTOR kinase inhibitors, containing the active ingredient everolimus. It is indicated for the treatment of advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and subependymal giant cell astrocytoma (tumours located in the ventricles of the brain). Good oral hygiene and regular dental check-ups are important during treatment, as this medicine can cause sores or ulcers in the mouth. For subependymal giant cell astrocytoma, it is often used in combination with cyclophosphamide, an alkylating agent.

Before commencing this medicine, patients should understand that the risk of bacterial or viral infection increases during this treatment. Patients with a history of Hepatitis B infection face an increased risk of reinfection with Advacan 0.25mg tablet. Inform your healthcare provider if you experience fever, chills, cough, yellowing of the skin, joint pain, or swelling during treatment. Limit your exposure to sunlight and UV light by wearing protective clothing and applying sunscreen regularly, as this medicine may increase the risk of developing cancers. Avoid consuming grapefruit juice or grapefruit while taking this medicine. This tablet is not recommended for patients under 18 years of age. Contact your doctor immediately if you experience shortness of breath, chest pain, or worsening cough.

During treatment with Advacan 0.25mg tablet, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes, and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Inform your doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Avoid live vaccines and close contact with individuals who have received live vaccines.

Advanced breast cancer Advanced renal cell carcinoma Advanced pancreatic neuroendocrine tumours Treatment of subependymal giant cell astrocytoma

Advacan 0.25mg tablet inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein and helps to reduce the size of tumours and improve outcomes in patients.

Take the Advacan 0.25mg tablet as advised by your physician. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Difficulty breathing, or swallowing Swelling of face, lips, tongue, throat Severe itching, red rash, raised bumps Common Infection (chills, increased temperature) Coughing Wheezing Excessive thirst High urine output or severely decreased urine output Tiredness Bleeding Increased appetite with weight loss

Advacan 0.25mg tablet has the tendency to cause harm to the unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or planning for pregnancy. Your healthcare provider will conduct a pregnancy test before you start treatment with this drug. Discuss effective birth control methods with your healthcare provider and use them during the treatment for 8 weeks after your last dose. This medicine passes into breast milk. Hence, it is not recommended to breastfeed during this treatment. The occurrence of mouth ulcers or sores is pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.